Publications by authors named "N Varsellona"
Article Synopsis
- Recent findings suggest that the decline in CA-125 levels is not a reliable indicator of treatment response in patients with recurrent ovarian cancer, prompting the use of mathematical modeling to analyze CA-125 dynamics.
- Data from the CALYPSO trial were examined using a semi-mechanistic model to understand factors influencing CA-125 levels during treatment and their correlation with progression-free survival (PFS).
- The study identified key kinetic parameters associated with PFS, confirming the unpredictable nature of traditional CA-125 response and highlighting the elimination rate (KELIM) as a potentially valuable predictive marker for patient outcomes.
Background: CALYPSO (CAeLYx in Platinum Sensitive Ovarian) patients compared carboplatin-pegylated liposomal doxorubicin (C-PLD) with carboplatin-paclitaxel (C-P) in patients with late-relapsing recurrent ovarian cancer (ROC). We analyzed outcomes in patients ≥70 years.
Patients And Methods: Nine hundred and seventy-six patients with taxane-pretreated ROC relapsing >6 months after first- or second-line platinum-based therapy were randomly assigned to 4-weekly C area under the curve (AUC) 5 plus PLD 30 mg/m(2) or 3-weekly C AUC 5 plus P 175 mg/m(2) for six or more cycles.